Success Metrics

Clinical Success Rate
100.0%

Based on 6 completed trials

Completion Rate
100%(6/6)
Active Trials
2(22%)
Results Posted
17%(1 trials)

Phase Distribution

Ph phase_1
5
56%
Ph phase_2
3
33%
Ph phase_3
1
11%

Phase Distribution

5

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
5(55.6%)
Phase 2Efficacy & side effects
3(33.3%)
Phase 3Large-scale testing
1(11.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

6 of 6 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

9

all time

Status Distribution
Active(3)
Completed(6)

Detailed Status

Completed6
Recruiting1
Active, not recruiting1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
2
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 15 (55.6%)
Phase 23 (33.3%)
Phase 31 (11.1%)

Trials by Status

recruiting111%
active_not_recruiting111%
not_yet_recruiting111%
completed667%

Recent Activity

2 active trials
Showing 5 of 9
recruitingphase_2

Olorofim in Early Coccidioidal Meningitis

NCT07385638
not_yet_recruitingphase_2

A Phase II Randomized Study to Evaluate Measures for Endpoint Derivation in Patients With Progressive or Refractory Disseminated Coccidioidomycosis (DCM ) Treated With Olorofim Plus Baseline SOC or Placebo Plus Baseline SOC

NCT07712484
active_not_recruitingphase_3

Olorofim Aspergillus Infection Study

NCT05101187
completedphase_2

Evaluate F901318 (Olorofim) Treatment of Invasive Fungal Infections in Participants Lacking Treatment Options

NCT03583164
completedphase_1

A Phase I Study to Assess the Pharmacokinetics of Olorofim in Subjects With Renal Impairment

NCT05200286
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT07385638Phase 2

Olorofim in Early Coccidioidal Meningitis

Recruiting
NCT07712484Phase 2

A Phase II Randomized Study to Evaluate Measures for Endpoint Derivation in Patients With Progressive or Refractory Disseminated Coccidioidomycosis (DCM ) Treated With Olorofim Plus Baseline SOC or Placebo Plus Baseline SOC

Not Yet Recruiting
NCT05101187Phase 3

Olorofim Aspergillus Infection Study

Active Not Recruiting
NCT03583164Phase 2

Evaluate F901318 (Olorofim) Treatment of Invasive Fungal Infections in Participants Lacking Treatment Options

Completed
NCT05200286Phase 1

A Phase I Study to Assess the Pharmacokinetics of Olorofim in Subjects With Renal Impairment

Completed
NCT04752540Phase 1

A Phase I Study to Assess the Pharmacokinetics of Olorofim in Subjects With Hepatic Impairment

Completed
NCT04207957Phase 1

A Biopharmaceutics Study to Assess the Pharmacokinetics of Single Oral and IV Doses of Olorofim

Completed
NCT04171739Phase 1

Drug-drug Interaction (DDI) Study to Assess Effect of Itraconazole and Rifampicin Upon Olorofim

Completed
NCT04039880Phase 1

Absorption, Metabolism and Excretion of 14C-olorofim in Man

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9